New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel
An FDA advisory committee has unanimously backed Moderna's first-of-its-kind mRNA seasonal influenza vaccine, triggering a surge in company stock.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
An FDA expert panel has voted unanimously in favor of the benefit-risk profile for mRNA-1010, an investigational seasonal influenza vaccine developed by Moderna. This represents a first-of-its-kind flu vaccine utilizing mRNA technology.
Coverage from the Los Angeles Times, CIDRAP, and ScienceAlert emphasizes the panel's endorsement of the vaccine. Yahoo Finance reports that Moderna's stock experienced its best week in over four years following the announcement, while Nature notes the vaccine expands B cell response breadth in humans.
Future developments depend on the final FDA decision following the advisory committee's recommendation regarding the investigational vaccine.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 12h ago.
Quick answers
What is the name of the investigational vaccine?
The vaccine is identified as mRNA-1010.
How did the FDA advisory committee vote?
The committee voted unanimously in favor of the vaccine's benefit-risk profile.
What technology does this flu vaccine use?
The vaccine uses mRNA technology.
Coverage (9)
- Moderna flu shot data may support use in older adults, US FDA staff says Reuters · 1d ago
- Moderna just got a signal investors can’t ignore Yahoo Finance · 1d ago
- FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy statnews.com · 1d ago
- mRNA-based influenza vaccine expands the B cell response breadth in humans Nature · 1d ago
- Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine Yahoo Finance · 1d ago
- FDA panel backs first-of-its-kind flu vaccine using mRNA technology Los Angeles Times · 1d ago
- MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu Vaccine Yahoo Finance · 1d ago
- Moderna’s mRNA flu vaccine gets thumbs up from federal vaccine panel CIDRAP · 1d ago
- New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel ScienceAlert · 1d ago
Topics
Related trends
Trump admin seeks to roll back testosterone restrictions
The Trump administration is pushing to ease restrictions on testosterone replacement therapy.